Patents Issued in May 16, 2024
  • Publication number: 20240156760
    Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
    Type: Application
    Filed: January 17, 2024
    Publication date: May 16, 2024
    Inventors: Hilde STEINEGER, David Alan FRASER, Tore SKJÆRET
  • Publication number: 20240156761
    Abstract: Provided is a dosage form comprising magnesium threonate having enhanced efficacy. Also provided is a pharmacokinetic profile of magnesium threonate having enhanced efficacy. The dosage forms and pharmacokinetic profile of magnesium threonate are used to treat a variety of diseases, disorders, syndromes and/or conditions.
    Type: Application
    Filed: June 15, 2023
    Publication date: May 16, 2024
    Inventors: Guosong LIU, Fei MAO, Jason Gregory WEINGER
  • Publication number: 20240156762
    Abstract: The present invention aims to provide a corosolic acid-containing beverage with an increased solubility of corosolic acid in water and a method of producing the same. The present invention relates to a corosolic acid-containing beverage that is a beverage containing corosolic acid, the beverage containing: at least one type of epicatechin compound selected from the group consisting of epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, wherein a corosolic acid content is 1 ppm or higher and corosolic acid is at least partially dissolved in the beverage.
    Type: Application
    Filed: March 15, 2022
    Publication date: May 16, 2024
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Shota Itoga, Shinya Fukizawa, Yuji Nonaka
  • Publication number: 20240156763
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: May 16, 2024
    Inventor: Remy Hanf
  • Publication number: 20240156764
    Abstract: A method of treating cancer in a subject in need thereof includes administering to the subject an agent that inhibits uracil-DNA glycosylase wherein the agent binds to UDG such that the UDG is maintained in a destabilized, open precatalytic glycosylase conformation that prevents active site closing for functional DNA binding and nuclease flipping needed to excise damaged bases binding in DNA.
    Type: Application
    Filed: March 1, 2023
    Publication date: May 16, 2024
    Inventor: Stanton Gerson
  • Publication number: 20240156765
    Abstract: This invention is directed to a method of preventing ocular neurodegeneration in a subject in need thereof.
    Type: Application
    Filed: January 23, 2024
    Publication date: May 16, 2024
    Inventor: Monica M. JABLONSKI
  • Publication number: 20240156766
    Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
    Type: Application
    Filed: September 8, 2023
    Publication date: May 16, 2024
    Applicant: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Publication number: 20240156767
    Abstract: A GLP-1 secretion promotion agent that includes a GPR84 agonist as an active ingredient.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 16, 2024
    Inventors: Ikuo Kimura, Ryuji Ohue, Miki Igarashi, Shinji Watanabe, Akiko Yamauchi
  • Publication number: 20240156768
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 16, 2024
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Robert GALLOTTO, Greta L. LORING, Kenneth GARY, Edward S. PARK, David J. BROWN, Willem Robert Klaas SCHOEVAART, Michiel Christian Alexander van VLIET
  • Publication number: 20240156769
    Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.
    Type: Application
    Filed: January 22, 2024
    Publication date: May 16, 2024
    Inventors: Hilde STEINEGER, David Alan FRASER, Tore SKJÆRET
  • Publication number: 20240156770
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: October 17, 2023
    Publication date: May 16, 2024
    Applicant: TECHFIELDS PHARMA CO., LTD.
    Inventor: Chongxi Yu
  • Publication number: 20240156771
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, chlorogenic acid, and, optionally, ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); chlorogenic acid; and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing ketosis and/or beta-oxidative activity in a subject. In addition, compositions that include concentrated forms of, and methods of using, chlorogenic acid (alone or in combination with short chain fatty acids and ketones) to induce ketogenesis in a subject are disclosed.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 16, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240156772
    Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
    Type: Application
    Filed: January 25, 2024
    Publication date: May 16, 2024
    Inventors: DANIEL M. CANAFAX, WILLIAM W. XIANG, LEONARD BLUM, JIA-NING XIANG
  • Publication number: 20240156773
    Abstract: A method for increasing the decanoic acid concentration in the peripheral blood and to deliver decanoic acid effective for manifesting a physiological action in the peripheral tissues without a large amount of MCT being ingested at one time. A method for increasing the blood decanoic acid concentration through ingestion of a triglyceride having, as constituent fatty acids, decanoic acid and long-chain fatty acids; a blood-decanoic-acid-concentration-increasing agent in which a triglyceride having, as constituent fatty acids, decanoic acid and long-chain fatty acids is employed as an active ingredient; and a pharmaceutical composition and a food composition that contain the blood-decanoic-acid-concentration-increasing agent.
    Type: Application
    Filed: March 16, 2022
    Publication date: May 16, 2024
    Inventors: Shogo TSUJINO, Tetsuo TAKAGI
  • Publication number: 20240156774
    Abstract: A composition containing a docetaxel albumin nanoparticle. The composition contains docetaxel and an acid-denatured albumin, wherein the acid-denatured albumin is obtained by means of adding an acid to human serum albumin to adjust the pH value. The composition can be prepared into an injection or a freeze-dried powder injection. A composition with satisfactory physical and chemical stability is obtained by means of controlling the content of sodium octanoate in human serum albumin, preferably in an acid denaturation condition.
    Type: Application
    Filed: March 4, 2022
    Publication date: May 16, 2024
    Inventors: Chunlei LI, Xiaojun ZHANG, Yuanyuan ZHAO, Dongjian CHEN, Min LIANG, Qianbin XING, Nan LI, Yun SHU
  • Publication number: 20240156775
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: January 18, 2024
    Publication date: May 16, 2024
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20240156776
    Abstract: Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express PfGARP.
    Type: Application
    Filed: February 28, 2022
    Publication date: May 16, 2024
    Inventors: Jonathan Kurtis, Andrew V. Oleinikov, Dipak K. Raj
  • Publication number: 20240156777
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Publication number: 20240156778
    Abstract: The present invention relates to a compound of formula (I) for use in a method for treating hepatic portal/periportal inflammation, optionally hepatic portal/periportal fibrosis.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 16, 2024
    Inventors: RAPHAËL DARTEIL, ERIC MELDRUM, JACKY VONDERSCHER
  • Publication number: 20240156779
    Abstract: Disclosed herein are methods for treating hyperparathyroidism, osteoporosis, or cancer cachexia, or inhibiting abnormally increased white adipose tissue browning, or decreasing the risk of a kidney stone in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a negative allosteric modulator of parathyroid hormone (PTH) type 1 receptor (PTHR) signaling.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 16, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ieva Sutkeviciute, Jean-Pierre Vilardaga, Jiyoung Lee, Ivet Bahar, Burak Kaynak
  • Publication number: 20240156780
    Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 16, 2024
    Applicant: Axial Therapeutics, Inc.
    Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
  • Publication number: 20240156781
    Abstract: Provided is a therapeutic agent for cellular drug resistance to a microtubule inhibitor. The therapeutic agent contains a ? opioid receptor agonist.
    Type: Application
    Filed: February 18, 2022
    Publication date: May 16, 2024
    Applicant: SOCIUM INC.
    Inventors: Katsuhisa HORIMOTO, Masashi KITAZAWA, Takayuki KIBOKU, Atsushi MIZOKAMI, Kouji IZUMI, Takashi SHIMADA
  • Publication number: 20240156782
    Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 16, 2024
    Applicant: Siga Technologies, Inc.
    Inventors: Shanthakumar R. TYAVANAGIMATT, Melialani A.C.L.S. ANDERSON, William C. WEIMERS, Dylan NELSON, Tove' C. BOLKEN, Dennis E. HRUBY, Michael H. O'NEILL, Gary SWEETAPPLE, Kelley A. McCLOUGHAN
  • Publication number: 20240156783
    Abstract: Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.
    Type: Application
    Filed: December 20, 2023
    Publication date: May 16, 2024
    Applicants: The Curators of the University of Missouri, The United States Government as Represented by the Department of Veterans Affairs
    Inventor: Rajiv R. Mohan
  • Publication number: 20240156784
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 16, 2024
    Inventors: Allison LIM, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin PATTERSON
  • Publication number: 20240156785
    Abstract: The present invention aims to provide a composition for improving a blood cholesterol level and a method of improving a blood cholesterol level. The present invention relates to a composition for improving a human blood cholesterol level, which contains L-ergothioneine or a salt thereof as an active ingredient.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 16, 2024
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Makoto Katsube, Hiroshi Watanabe, Norihito Murayama
  • Publication number: 20240156786
    Abstract: Provided herein are gel compositions comprising oxymetazoline, and their use for treatment of blepharitis.
    Type: Application
    Filed: March 2, 2022
    Publication date: May 16, 2024
    Inventor: Mark Silverberg
  • Publication number: 20240156787
    Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
    Type: Application
    Filed: January 24, 2024
    Publication date: May 16, 2024
    Inventors: Bhavya Teja KOLLA, Rahul SURANA, Suketu SANGHVI, Jigar BHATT
  • Publication number: 20240156788
    Abstract: In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 16, 2024
    Inventors: John Gunn, Laura Kuo, Christian Melander, William M. Huggins
  • Publication number: 20240156789
    Abstract: An oral feline feed and a method of controlling fleas in a feline in need thereof by orally administering to the feline a daily feed comprising an effective amount of an isoxazoline for an effective time to thereby cause the amount of isoxazoline in the feline's blood to rise to and maintain at a therapeutically effective level for controlling fleas.
    Type: Application
    Filed: December 18, 2023
    Publication date: May 16, 2024
    Inventors: Robin S. Readnour, Kevin E. Willard, Joseph R. Winkle
  • Publication number: 20240156790
    Abstract: The present disclosure provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.
    Type: Application
    Filed: November 24, 2023
    Publication date: May 16, 2024
    Inventors: Brent R. STOCKWELL, Arie ZASK, Hui TAN, Jacob D. DANIELS
  • Publication number: 20240156791
    Abstract: In some embodiments, a method of treating spinal cord injury or damage, or a complication thereof, in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I, Ia, Ik, or II.
    Type: Application
    Filed: February 18, 2022
    Publication date: May 16, 2024
    Inventors: Stella T. Sarraf, Vincent F. Simmon, Peter W. Vanderklish
  • Publication number: 20240156792
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Application
    Filed: January 25, 2024
    Publication date: May 16, 2024
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Akira KANOH
  • Publication number: 20240156793
    Abstract: The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 16, 2024
    Inventors: Alpa B. PARIKH, John C. McKEW
  • Publication number: 20240156794
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 16, 2024
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • Publication number: 20240156795
    Abstract: Compositions and methods for the treatment of topical infections such as onychomycosis are disclosed.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 16, 2024
    Inventors: Melvin Reichman, George C. Prendergast
  • Publication number: 20240156796
    Abstract: The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective ?-opioid receptor agonist as an active component, wherein the selective ?-opioid receptor agonist preferably also has a ?-opioid receptor antagonist action and a ?-opioid receptor antagonist action.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 16, 2024
    Applicants: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akiyoshi SAITOH, Daisuke YAMADA, Eriko NAKATA
  • Publication number: 20240156797
    Abstract: A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.
    Type: Application
    Filed: January 25, 2024
    Publication date: May 16, 2024
    Inventors: Brett Hale Davis, Caleb Adrian Lade, Sierra Nichelle Erickson, Susan Alice Wojtalewicz
  • Publication number: 20240156798
    Abstract: Disclosed herein are compositions comprising antioxidants and methods of use thereof.
    Type: Application
    Filed: October 24, 2023
    Publication date: May 16, 2024
    Inventor: Dennis J. Carlo
  • Publication number: 20240156799
    Abstract: Embodiments of the present disclosure relate to methods of using bupivacaine multivesicular liposomes as stellate ganglion block for treating or ameliorating an anxiety disorder or a traumatic brain injury associated with overactive or unbalanced sympathetic nervous system, including but not limited to, generalized anxiety disorders, panic disorder, and post-traumatic stress disorder.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 16, 2024
    Inventors: John Spranger, Roy Winston, Jonathan Slonin
  • Publication number: 20240156800
    Abstract: The present invention relates to methods for treating a disease or disorder associated with EP300 dependency and elevated CRBN expression levels (e.g., cancer (e.g., neuroblastoma)).
    Type: Application
    Filed: March 8, 2022
    Publication date: May 16, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Adam D. Durbin
  • Publication number: 20240156801
    Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.
    Type: Application
    Filed: June 7, 2023
    Publication date: May 16, 2024
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Garry A. Neil, Liza Squires, Hakon Hakonarson
  • Publication number: 20240156802
    Abstract: Provided herein are methods of treating a disorder ameliorated by activating muscarinic receptors in a patient 55 years or older in need thereof. The method comprises administering a total daily dose of between 25 and 200 mg xanomeline and/or a salt thereof and between 5 and 30 mg of a salt of trospium to the patient, such as a total daily dose of between 100 and 200 mg xanomeline and/or a salt thereof and between 20 and 30 mg of a salt of trospium. The present disclosure also provides a method for treating dementia-related psychosis and a method decreasing the risk of relapse in a patient having dementia-related psychosis.
    Type: Application
    Filed: August 23, 2023
    Publication date: May 16, 2024
    Inventors: Andrew MILLER, Stephen BRANNAN, Inderjit KAUL, Ronald N. MARCUS, David S. SMALL
  • Publication number: 20240156803
    Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
    Type: Application
    Filed: January 26, 2024
    Publication date: May 16, 2024
    Inventors: David Smith, Maha Hussain
  • Publication number: 20240156804
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 16, 2024
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20240156805
    Abstract: The present invention relates to a compound for inhibition of nonsense-mediated mRNA decay (hereinafter referred to as “NMD”) or a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related disease through the NMD-inhibiting compound.
    Type: Application
    Filed: February 15, 2022
    Publication date: May 16, 2024
    Applicant: RIBOTECH CO., LTD.
    Inventor: Yoon Ki KIM
  • Publication number: 20240156806
    Abstract: Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 16, 2024
    Applicant: Corcept Therapeutics Incorporated
    Inventors: Grace Mann, Iulia Cristina Tudor, William Guyer, Hazel Hunt, Joseph Custodio
  • Publication number: 20240156807
    Abstract: Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery.
    Type: Application
    Filed: October 14, 2020
    Publication date: May 16, 2024
    Applicant: Corcept Therapeutics Incorporated
    Inventors: Andrew Greenstein, Lawrence Lu, Joseph Custodio, Stacie Shepherd
  • Publication number: 20240156808
    Abstract: The present invention is directed to improved methods, formulations, and compositions employing substituted camptothecins such as, but not limited to, irinotecan and topotecan as well as analogs, derivatives, and prodrugs thereof. These methods, formulations, and compositions can be used to treat malignancies and other diseases and conditions including, but not limited to, non-malignant proliferative disorders, infections, inflammatory, and immunological diseases.
    Type: Application
    Filed: February 22, 2022
    Publication date: May 16, 2024
    Inventor: DENNIS BROWN
  • Publication number: 20240156809
    Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 16, 2024
    Applicant: BioDelivery Sciences International, Inc.
    Inventors: Andrew Finn, Niraj Vasisht